HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 101-105

  Chen, Wen Ting ^a,b   Gao, Xiang ^a,b   Han, Xiao Dian ^a   Zheng, Hui ^a   Guo, Lin ^a,b   Lu, Ren Quan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biomarker; CA125; Human epididymis protein 4; Ovarian cancer; Prognosis

Indexed keywords

CA 125 ANTIGEN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ALGORITHM; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; METABOLISM; NEOPLASM; OVARY TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR RECURRENCE;

ALGORITHMS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84894087783     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.101     Document Type: Article

References (29)

1. Allard J, Somers E, Theil R, et al (2008). Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. J Clin Oncol, 26, 5535.
2. Andersen MR, Goff BA, Lowe KA, et al (2008). Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer, 113, 484-9.
3. Anton C, Carvalho FM, Oliveira EI, et al (2012). A Comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. CLINICS, 67, 437-41.
4. Bouchard D, Morisset D, Bourbonnais Y, et al (2006). Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol, 7, 167-74.
5. Devan SM, Pailoor J, Sthaneshwar P, et al (2013). Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 Levels. Asian Pac J Cancer Prev, 14, 4545-8.
6. Drapkin R, Henning von Horsten H, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9.
7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
8. Ferraro S, Braga F, Lanzoni M, et al (2013). Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol, 66, 273-81.
9. Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol, 110, 374-82.
10. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63, 3695-700.
11. Hynninen J, Auranen A, Dean K, et al (2011). Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer, 21, 1573-8.
12. Lokshin AE (2012). The quest for ovarian cancer screening biomarkers: are we on the right road? Int J Gynecol Cancer, 22, S35-40.
13. Lu RQ, Hu J, Guo L (2009). Evaluation of human epididymis protein 4 as a biomarker in patients with ovarian cancer. Chin J Lab Med, 32, 1379-83.
14. Lu RQ, Guo L, Shen YH (2010). The roles of human epididymis protein 4 in patients with ovarian cancer. China Oncol, 20, 585-90.
15. Macuks R, Baidekalna I, Donina S (2012). An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumor Biol, 33, 1811-7.
16. Maggino T, Gadducci A, D'Addario V, et al (1994). Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol, 54, 117-23.
17. Miralles C, Orea M, Espana P, et al (2003). Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol, 10, 150-4.
18. Mokhtar NM, Thevarajah M, Noorazmi MA, et al (2013). Human epididymis protein 4 reference intervals in a multiethnic Asian women population. Asian Pacific J Cancer Prev, 13, 6391-5.
19. Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108, 402-8.
20. Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112, 40-6.
21. Moore RG, Jabre-Raughley M, Brown AK, et al (2010). Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol, 203, e221-6.
22. Park Y, Kim Y, Lee EY (2012). Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer, 130, 1136-44.
23. Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 99, 267-77.
24. Ruggeri G, Bandiera E, Zanotti L, et al (2011). HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta, 412, 1447-53.
25. Rustin GJ, Vergote I, Eisenhauer E, et al (2011). Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21, 419-23.
26. Schummer M, Drescher C, Forrest R, et al (2012). Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol, 125, 65-9.
27. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
28. Speeckaert MM, Speeckaert R, Delanghe JR (2013). Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem, 59, 1-21.
29. Su ZL, Graybill WS, Zhu YS (2013). Detection and monitoring of ovarian cancer. Clinica Chimica Acta, 415, 341-5.